EGFR and lung carcinoma: A pivotal challenge is to understand how the major driver mutations—EGFR L858R and Ex19del—affect disease-related downstream networks together with other upstream driver mutation crosstalk, which plays a central role in the context of lung cancer progression, malignancy, and outcome and/or resistance regarding TKI therapies (28).